Switch theme
Sign up to access all valuation multiples
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products.
1984
1.4K+
LTM Revenue $136M
LTM EBITDA $56.0M
$2.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Concord Biotech has a last 12-month revenue of $136M and a last 12-month EBITDA of $56.0M.
In the most recent fiscal year, Concord Biotech achieved revenue of $116M and an EBITDA of $54.4M.
Concord Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Concord Biotech valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $96.5M | $116M | XXX | XXX | XXX |
| Gross Profit | $61.6M | $73.6M | XXX | XXX | XXX |
| Gross Margin | 64% | 63% | XXX | XXX | XXX |
| EBITDA | $44.2M | $54.4M | XXX | XXX | XXX |
| EBITDA Margin | 46% | 47% | XXX | XXX | XXX |
| Net Profit | $20.3M | $27.9M | XXX | XXX | XXX |
| Net Margin | 21% | 24% | XXX | XXX | XXX |
| Net Debt | $7.0M | $3.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Concord Biotech's stock price is INR 1653 (or $19).
Concord Biotech has current market cap of INR 173B (or $2.0B), and EV of INR 170B (or $2.0B).
See Concord Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.0B | $2.0B | XXX | XXX | XXX | XXX | $0.39 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Concord Biotech has market cap of $2.0B and EV of $2.0B.
Concord Biotech's trades at 14.5x LTM EV/Revenue multiple, and 35.2x LTM EBITDA.
Analysts estimate Concord Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Concord Biotech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.0B | XXX | XXX | XXX |
| EV/Revenue | 15.2x | XXX | XXX | XXX |
| EV/EBITDA | 35.7x | XXX | XXX | XXX |
| P/E | 50.9x | XXX | XXX | XXX |
| P/E/Growth | 2.2x | XXX | XXX | XXX |
| EV/FCF | 81.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpConcord Biotech's NTM/LTM revenue growth is 21%
Concord Biotech's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $31K for the same period.
Over next 12 months, Concord Biotech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Concord Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Concord Biotech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 43% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 63% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $31K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 37% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Concord Biotech acquired XXX companies to date.
Last acquisition by Concord Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Concord Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Concord Biotech founded? | Concord Biotech was founded in 1984. |
| Where is Concord Biotech headquartered? | Concord Biotech is headquartered in India. |
| How many employees does Concord Biotech have? | As of today, Concord Biotech has 1.4K+ employees. |
| Who is the CEO of Concord Biotech? | Concord Biotech's CEO is Mr. Ankur Vaid. |
| Is Concord Biotech publicy listed? | Yes, Concord Biotech is a public company listed on BOM. |
| What is the stock symbol of Concord Biotech? | Concord Biotech trades under 543960 ticker. |
| When did Concord Biotech go public? | Concord Biotech went public in 2023. |
| Who are competitors of Concord Biotech? | Similar companies to Concord Biotech include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Concord Biotech? | Concord Biotech's current market cap is $2.0B |
| What is the current revenue of Concord Biotech? | Concord Biotech's last 12-month revenue is $136M. |
| What is the current EBITDA of Concord Biotech? | Concord Biotech's last 12-month EBITDA is $56.0M. |
| What is the current EV/Revenue multiple of Concord Biotech? | Current revenue multiple of Concord Biotech is 14.5x. |
| What is the current EV/EBITDA multiple of Concord Biotech? | Current EBITDA multiple of Concord Biotech is 35.2x. |
| What is the current revenue growth of Concord Biotech? | Concord Biotech revenue growth between 2023 and 2024 was 20%. |
| Is Concord Biotech profitable? | Yes, Concord Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
